|By Marketwired .||
|June 12, 2014 04:01 PM EDT||
TORONTO, ONTARIO -- (Marketwired) -- 06/12/14 -- BioSyent Inc. ("BioSyent") (TSX VENTURE: RX) is pleased to announce that Canadian Business and PROFIT has ranked BioSyent as one of Canada's Fastest-Growing Companies in the just released 2014 rankings. Published in the July issue of Canadian Business and online at PROFITguide.com, the PROFIT 500 ranks Canadian businesses by their revenue growth over five years. Based upon a five year revenue (2008-2013) growth rate of 608%, BioSyent ranked 104 on the PROFIT 500 list. This is the second consecutive year that BioSyent has been named to the Profit 500 list and marks a significant increase in 5 year growth rate, from 355% on last year's list to 608% on this year's list.
For a direct market quote (15 minutes delay) for the TSX Venture Exchange and other Company financial information please visit www.tmxmoney.com.
About BioSyent Inc.
Listed on the Toronto Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth oriented specialty pharmaceutical company which searches the globe to in-license or acquire innovative pharmaceutical products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients and supporting the healthcare professionals that treat them.
Once a product of interest has been found, BioSyent then acquires the exclusive rights to the product and manages it through the Canadian governmental regulatory approval process. Once approved, BioSyent markets the product throughout Canada.
At the date of this press release the Company had 13,801,195 shares issued and outstanding.
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
The TSX Venture Exchange assumes no responsibility for the accuracy of this release and neither approves nor disapproves of the same.
Sep. 26, 2016 01:30 PM EDT Reads: 1,149
Sep. 26, 2016 01:15 PM EDT Reads: 3,291
Sep. 26, 2016 01:00 PM EDT Reads: 1,608
Sep. 26, 2016 12:45 PM EDT Reads: 3,409
Sep. 26, 2016 12:45 PM EDT Reads: 2,034
Sep. 26, 2016 12:45 PM EDT Reads: 2,248
Sep. 26, 2016 12:45 PM EDT Reads: 1,733
Sep. 26, 2016 12:15 PM EDT Reads: 2,661
Sep. 26, 2016 12:15 PM EDT Reads: 1,666
Sep. 26, 2016 12:00 PM EDT Reads: 2,791
Sep. 26, 2016 12:00 PM EDT Reads: 1,379
Sep. 26, 2016 11:45 AM EDT Reads: 2,440
Sep. 26, 2016 11:30 AM EDT Reads: 995
Sep. 26, 2016 11:30 AM EDT Reads: 2,577
Sep. 26, 2016 11:30 AM EDT Reads: 2,541